Nasdaq
$10.22▲ 0.39%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $1.76BShares out 1.700M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
20- 10.14Pre-market26.10.14 20:088-KKey event#●●●#●●●#●●●
Xeris Biopharma Holdings, Inc.
Xeris Biopharma Holdings has filed patent infringement lawsuits in the U.S. District Court for the District of New Jersey against Torrent Pharma and Rising Pharma entities. The legal action follows the issuance of U.S. Patent No. 12,758,502 regarding the company's KEVEYIS (dichlorphenamide) product, with the company seeking injunctive relief and monetary damages against the defendants' generic versions.…more
$10.22+0.39%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.2After-hours26.10.03 05:544Ownership
Xeris Biopharma Holdings, Inc.
Insider Steven Pieper of Xeris Biopharma Holdings filed a Form 4 on October 2, 2026, reporting changes in beneficial ownership of securities as of October 1, 2026. This filing serves as a standard disclosure of insider equity transactions and does not involve significant corporate capital restructuring.…more
$10.22+0.39%vs prev closeView filingShare - 10.2After-hours26.10.03 05:544Ownership
Xeris Biopharma Holdings, Inc.
Insider Kevin McCulloch of Xeris Biopharma Holdings reported a change in beneficial ownership of securities as of October 1, 2026. This filing is a Form 4 statement detailing the executive's equity position.…more
$10.22+0.39%vs prev closeView filingShare
19 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.14Pre-market26.10.14 20:12#●●●#●●●#●●●
Xeris Biopharma Files Patent Infringement Lawsuits for KEVEYIS
Xeris Biopharma has filed patent infringement lawsuits against several generic drug manufacturers regarding its KEVEYIS product. The company is seeking injunctive relief and monetary damages to protect its newly granted patent rights.…more
$10.22+0.39%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 9.29Regular26.09.30 01:37
●●●●●●●● ●●●●● ●●●●●●
Reports suggest that Lundbeck is exploring a potential acquisition of Xeris Biopharma. As no formal agreement or financial details have been confirmed, the news remains speculative.…more
$10.22+0.39%vs prev closeShareBenzinga - 9.9Pre-market26.09.09 21:34
●●●●●●●● ●●●●● ●●●●●●
Xeris Biopharma has detailed the clinical development strategy and commercial potential for its once-weekly hypothyroidism treatment, XP-8121. The company expects top-line Phase 3 results in late 2028, with FDA approval and market launch targeted for 2030.…more
$10.22+0.39%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report